What is Cancer News Daily?

Cancer News Daily is a comprehensive cancer research news aggregator that collects and curates the latest research articles from 120+ trusted medical journals and cancer research institutions worldwide. We provide free access to breakthrough treatments, clinical trials, nutrition research, and new technology in oncology.

How often is content updated?

Our automated system fetches new cancer research articles every 2 hours from 120+ authoritative medical journals across 5 continents, ensuring you always have access to the latest breakthroughs.

What sources does Cancer News Daily aggregate from?

We aggregate content from 120+ trusted sources including top-tier journals like Nature Cancer, The Lancet Oncology, JAMA Oncology, Cancer Cell, major cancer centers like MD Anderson and Memorial Sloan Kettering, government organizations like NCI and NIH, and international research institutions across North America, Europe, Asia-Pacific, and beyond.

Is Cancer News Daily free to use?

Yes, Cancer News Daily is completely free to access. We believe life-saving cancer research should be accessible to everyone - patients, caregivers, researchers, and medical professionals worldwide.

HER2-positive gastroesophageal cancer: meaningful progress, unresolved biology

Annals of Oncology | February 23, 2026 | H.W.M. van Laarhoven, M.F. Bijlsma

KCWISE is a randomized phase III trial evaluating anbenitamab plus chemotherapy (paclitaxel, docetaxel or irinotecan) versus chemotherapy alone in trastuzumab-pretreated, HER2-positive gastric/GEJ cancer.1 Preplanned interim analysis showed a substantial improvement in progression free survival (PFS) benefit (median 7.1 versus 2.7 months; hazard ratio [HR] 0.25; p<0.0001) and a strong early overall survival (OS) signal (median 19.6 versus 11.5 months; HR,…

Topics: breast-cancer, blood-cancer, esophageal-cancer, chemotherapy, clinical-trials

Read the full article at Annals of Oncology